急性髓系白血病中 AML1-ETO 和 MLL-AF9 融合基因表达与血液学参数的关系。

Relationships between AML1-ETO and MLL-AF9 fusion gene expressions and hematological parameters in acute myeloid leukemia.

机构信息

Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Taibah University, Medina, Kingdom of Saudi Arabia.

Faculty of Medical Laboratory Science, Department of Hematology and Blood Transfusion, Alzaeim Alazhari University, Khartoum, Sudan.

出版信息

Gulf J Oncolog. 2020 Sep;1(34):65-69.

PMID:33431365

Abstract

BACKGROUND

Acute myeloid leukemia (AML) is a malignant disease of the myeloid line that caused by several chromosomal aberrations that include AML1 -ETO and MLL-AF9. In the current study, the correlations of fusion gene quantitative RT-PCR and hematological parameters in patients with AML were examined to determine their prognostic value in clinical practice.

METHODOLOGY

This study was conducted at Alzaeim Alazhari University, Khartoum, Sudan. A total of 82 patients with AML (51 AML1-ETO and 31 MLL-AF9) were participated in the study. Quantitative RT-PCR was used to determine types of fusion genes Results: The expression of MLL-AF9 was significantly higher than that for AML1-ETO (P < 0.01). In addition, with respect to FAB classification M2/M3 types were dominated in patients with AML1-ETO gene fusion, whereas M4/M5 types were dominated in MLL-AF9 subjects (P < 0.01). Finally, neither AML1-ETO nor MLL-AF9 quantitative RT-PCR gene expressions were correlated with the examined hematological parameters including: hemoglobin, total white blood count, platelets and blast cells (P > 0.05).

CONCLUSIONS

Significant variations in AML1-ETO and MLL-AF9 expression were observed in AML. No correlations between the expression of fusion genes and hematological parameters were detected.

摘要

背景

急性髓系白血病（AML）是一种由多种染色体异常引起的骨髓系恶性疾病，其中包括 AML1-ETO 和 MLL-AF9。在本研究中，我们研究了 AML 患者中融合基因定量 RT-PCR 与血液学参数的相关性，以确定其在临床实践中的预后价值。

方法

本研究在苏丹喀土穆的 Alzaeim Alazhari 大学进行。共纳入 82 例 AML 患者（51 例 AML1-ETO 和 31 例 MLL-AF9）。采用定量 RT-PCR 法确定融合基因类型。

结果

MLL-AF9 的表达明显高于 AML1-ETO（P<0.01）。此外，就 FAB 分类而言，AML1-ETO 基因融合患者以 M2/M3 型为主，而 MLL-AF9 患者以 M4/M5 型为主（P<0.01）。最后，AML1-ETO 和 MLL-AF9 的定量 RT-PCR 基因表达均与血红蛋白、总白细胞计数、血小板和原始细胞等血液学参数无关（P>0.05）。